Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Jun 5;353(9168):1909-14.

16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer

No authors listed
  • PMID: 10371568
Clinical Trial

16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer

No authors listed. Lancet. .

Abstract

Background: The UK Trial of Early Detection of Breast Cancer (TEDBC) is a non-randomised study, which was set up in 1979 to investigate the effect of screening and education about breast self-examination on breast-cancer mortality. We report mortality results after 16 years of follow-up, including results by age at trial entry.

Methods: Eight centres (two screening, two breast self-examination, and four comparison) in England and Scotland recruited women aged 45-64 years into the initial cohort, with women reaching age 45 years during the 7-year study period included in later cohorts. The observed number of deaths from breast cancer in each centre was compared with the expected number, which was calculated by Poisson regression model; expected numbers were adjusted for pretrial breast-cancer mortality. Results were analysed by 5-year age-groups, and for women aged 45-46 years and 47-49 years at entry.

Findings: Breast-cancer mortality was 27% lower (rate ratio 0.73 [95% CI 0.63-0.84]), adjusted for pretrial rates, in cohort 1 in the two screening centres combined than in the comparison centres. No reduction in mortality in the two breast self-examination centres combined was seen (rate ratio 0.99 [0.87-1.12]). The mortality reduction in the screening centres did not differ significantly across age-groups; a 35% reduction was seen in women in all cohorts aged 45-46 years at entry (rate ratio 0.65 [0.50-0.86]). Results were similar when deaths were restricted to those in patients diagnosed within 10 years of trial entry.

Interpretation: The results from TEDBC support those from randomised trials in Edinburgh and elsewhere, and show that a reduction in breast-cancer mortality resulting from screening can be achieved in the UK. There was no evidence of less benefit in women aged 45-46 years at the start of screening; the effect of screening in this age-group begins to emerge after 3-4 years.

PubMed Disclaimer

Comment in

Similar articles

Cited by

Publication types

LinkOut - more resources